|Mr. Robert M. Davis J.D.||CEO & Chairman||4.4M||N/A||1967|
|Ms. Caroline Litchfield||Exec. VP & CFO||2.05M||782.81k||1969|
|Mr. Richard R. DeLuca Jr.||Exec. VP & Pres of Merck Animal Health||2.05M||6.11M||1963|
|Dr. Dean Y. Li M.D., Ph.D.||Exec. VP & Pres of Merck Research Laboratories||2.4M||N/A||1962|
|Mr. David Michael Williams||Exec. VP and Chief Information & Digital Officer||N/A||N/A||1969|
|Mr. Peter Dannenbaum||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Jennifer L. Zachary||Exec. VP & Gen. Counsel||N/A||N/A||1978|
|Lisa LeCointe-Cephas||Sr. VP and Chief Ethics & Compliance Officer||N/A||N/A||1982|
|Ms. Cristal N. Downing||Exec. VP and Chief Communications & Public Affairs Officer||N/A||N/A||1970|
|Mr. Steven C. Mizell||Exec. VP & Chief HR Officer||N/A||N/A||1960|
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc.’s ISS governance QualityScore as of 1 February 2023 is 3. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 3; Compensation: 5.